Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108452 | 0.89 | ALDH1A1 (0.60) | CA1CA2ALDH1A1HSD17B10PKM | |
| SCHEMBL10108455 | 0.84 | ALDH1A1 (0.61) | CA1CA2ALDH1A1HSD17B10PKM | |
| SCHEMBL11479937 | 0.82 | RECQL (0.65) | CA1CA2RECQLALDH1A1HSD17B10 | |
| SCHEMBL11893032 | 0.82 | PKM (0.54) | CA1CA2ALDH1A1HSD17B10PKM | |
| SCHEMBL12829988 | 0.80 | AKT1 (0.49) | ALDH1A1PKM | |
| SCHEMBL5398574 | 0.77 | ALDH1A1 (0.73) | CA1CA2RECQLALDH1A1HSD17B10 | |
| SCHEMBL11893082 | 0.76 | ALDH1A1 (0.77) | CA1CA2RECQLALDH1A1PKM | |
| SCHEMBL10108458 | 0.76 | AKT1 (0.53) | ALDH1A1HSD17B10PKMLMNA | |
| SCHEMBL5410329 | 0.75 | ALDH1A1 (0.81) | CA1CA2RECQLALDH1A1HSD17B10 | |
| SCHEMBL14582751 | 0.74 | CA1 (0.65) | CA1CA2RECQLALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120189670-A1 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PHUSIS THERAPEUTICS INC. | 2012-07-26 | — | — | US | disclosed |
| EP-2428504-A1 | Small molecule inhibitors of the pleckstrin homology domain and method for using same | The Board of Regents of the University of Texas System (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2009129267-A2 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEKHA1, PLEC | CA1 4268/4885CA2 3465/4885RECQL 1845/4885 |
| US-20120189670-A1 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEC, PLEKHA1 | CA1 4338/4885CA2 3474/4885RECQL 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.